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The growing threat of nontuberculous
mycobacteria in CFThere has been recent growing awareness of the threat of
nontuberculous mycobacteria (NTM) to individuals with cystic
fibrosis (CF) and an increasing appreciation of the difficulties
in screening, diagnosing and treating NTM-pulmonary infec-
tion in the context of CF lung disease. Forthcoming joint US
CFF-ECFS guidelines have been developed to assist clinicians
with the management of NTM in individuals with CF.
There are two main groups of NTM that cause the majority
of infections in individuals with CF: the Mycobacterium avium
complex (MAC) consisting of M. avium, M. intracellulare and
M. chimaera; and theM. abscessus complex (MABSC) made up
of three subspecies, M. abscessus spp. abscessus, M. abscessus.
spp. massiliense and M. abscessus spp. bolettii. While MAC is
the more common infection in the US [1], studies have suggested
that MABSC is more frequent in Europe [2] and elsewhere [3].
Moreover, the rates ofMABSC infection appear to be rising across
the world [4,5]; a positive sputum culture for MABSC is more
likely to indicate the presence of NTM-mediated lung damage
(termed ‘NTM pulmonary disease’) rather than asymptomatic
colonisation [6]; and treatment of MABSC remains extremely
difficult [7].
This issue of the Journal of Cystic Fibrosis publishes three
studies on aspects of NTM infection in CF [8–10], which
highlight the growing challenge of NTM to individuals with
CF.
A retrospective analysis by Qvist et al. [8] of data from
Danish, Swedish and Norwegian CF centres between 2000 and
2012 identified 11% (157/1270) patients with at least one
positive NTM culture during this period. Interestingly higher
rates of NTM were detected in larger centres, such as
Copenhagen (13%) and Gothenberg (28%) than in smaller
units, such as Aarhus (3%), possibly reflecting heightened
clinician awareness or, more worryingly, greater opportunities
for cross-infection.
Bar-on et al. [9] undertook a retrospective study in a single
CF Centre in Israel from 2002 to 2011. Commendably, both
the microbiological analysis of sputum samples (decontami-
nation and culture protocols) and the sampling intensity were
kept constant throughout this period, thus permitting robust
assessment of longitudinal changes in infection rates. Annual
incidence of new NTM positive cultures increased from 0% in
2002 to 9% in 2011. This study also measured serum cytokineshttp://dx.doi.org/10.1016/j.jcf.2014.12.002
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with M. abscessus-positive sputum samples had higher levels
of serum TNFα, IL-1β and TGFβ than non-infected controls,
suggesting a clear systemic inflammatory signal associated
with infection.
Both Scandinavian and Israeli studies reveal thatM. abscessus
is the most common NTM species found in CF individuals, that
individuals becoming infected with NTM infection have very
good lung function (dispelling the myth that this organism has a
predilection for advanced CF lung disease), and that treatment
frequently fails to achieve culture conversion.
The study by Roux et al. [10] compared the clinical features
of individuals infected with the M. abscessus spp. massiliense
to those infected with M. abscessus spp. abscessus using data
obtained from a national survey of NTM in France carried out
between 2001 and 2004which sampled 41 out of 49 CF centres in
the country. Of individuals with two or more positive cultures,
those withM. abscessus spp. massiliense infection (n = 16) were
younger and had lower BMI than individuals with M. abscessus
spp. abscessus infection (n = 27), suggesting potentially different
host susceptibilities for these pathogens. Analysis of treatment
response for the two subspecies was severely limited by numbers
(follow-up data were available for only 7 patients with M. a.
massiliense and 14 with M. a. abscessus infection), and by the
inclusion of individuals with asymptomatic infection not fulfilling
ATS/IDSA criteria for NTM-pulmonary disease. Nevertheless, this
study supports previous reports that indicate thatM. abscessus spp.
massiliense may be easier to treat than the M. abscessus spp.
abscessus subspecies [11,12], although caution may be necessary
in evaluating these results from a decade ago. The emergence of
multidrug resistant clones ofM. abscessus spp.massiliense capable
of person-to-person transmission (despite conventional infection
control measures), so far detected in the UK and USA [13–15],
may have a global impact on both the numbers of individuals
currently infected and our ability to successfully treat them.
What can be done about the growing problem of NTM in
CF? These papers highlight an urgent need to collect detailed
international prospective data to better define the changing
epidemiology, burden of disease and response to treatment of
NTM infection. Moreover, we now have an opportunity to
establish systematic whole genome sequencing of clinical
isolates of NTM to track person-to-person transmission acrossll rights reserved.
2 Editorialthe continent and evaluate enhanced infection control mea-
sures where these have been implemented (for example in the
UK [16]). While the ECFSWorking Group on NTM has begun
to establish a network of interested clinicians willing to deliver
both investigator-led and commercial trials into novel thera-
pies, more work needs to be done if we are to meet the global
challenge of NTM infection to the CF community.
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